The year 2026 marks the beginning of the 15th Five-Year Plan period. Recently, the 11th batch of the “Outstanding Domestic Medical Equipment Product Catalogue” was officially released. Viestar’s independently developed BIOPSEE® Confocal Laser Endomicroscope and BIOPSEE® Ultra-Thin Probe-based Confocal Laser Endomicroscope were prominently selected. This recognition makes JWS Medical the exclusive selected product in the confocal microscopy field for this batch, securing a “strong start” for the 15th Five-Year Plan with national-level authoritative certification. This achievement lays a solid foundation for the company to accelerate development and lead the industry throughout the year.
This selection process was initiated by the National Health Commission and led by the China Association of Medical Equipment. It employed the industry’s most rigorous, full-dimension quantitative standards, evaluating key aspects such as core technology level, clinical application value, mass production capability, and comprehensive innovation strength. The final selected products represent the industry’s highest standards, serving as both an authoritative procurement guide for medical institutions nationwide and a top-tier national endorsement of product strength and industry status.
As a global technology leader in the field of microendoscopy,Viestar has consistently focused on independent innovation across its core technology value chain. The company has broken international technological barriers, filled domestic industrial gaps, and built a self-controlled, complete industrial chain system. The two selected products, recognized for their globally leading technology, excellent and extensively clinically validated application value, and mature, stable industrialization capabilities, stood out among numerous applicants, becoming the sole selected products in the confocal microscopy category for this catalogue. This achievement solidly demonstrates the company’s benchmark industry position and global competitiveness.
Efung Capital participated in the financing round for Viestar in 2025, taking concrete action to support long-term development in the hard-tech innovation sector of advanced medical devices. Standing at the new starting point of the “15th Five-Year Plan,” Efung remains committed to its long-term strategy.